Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping.

Journal of pharmaceutical and biomedical analysis - 15 Oct 2024

van den Wildenberg Sebastian A H, Genet Sylvia A A M, Streng Alexander S, Broeren Maarten A C, Deenen Maarten J, van Dongen Joost L J, Brunsveld Luc, Scharnhorst Volkher, van de Kerkhof Daan

Abstract excerpt

Fluorouracil is among the most used antimetabolite drugs for the chemotherapeutic treatment of various types of gastrointestinal malignancies. Dihydropyrimidine dehydrogenase (DPYD) genotyping prior to fluorouracil treatment is considered standard practice in most European countries. Yet, current pre-therapeutic DPYD genotyping procedures do not identify all dihydropyrimidine dehydrogenase (DPD)-deficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Liquid
Share to Dihydrouracil Dehydrogenase (NADP)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Genotype

Share to Protein Binding

Share to Tandem Mass Spectrometry

Share to Thymine

Share to Uracil

Source

Identifiers

PMID: 39067280
DOI: 10.1016/j.jpba.2024.116381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping.PMID 39067280Read ↗

An optimized HPLC-MS/MS assay for uracil and dihydrouracil in plasma: Improving dihydropyrimidine dehydrogenase phenotyping for individualized fluoropyrimidine treatment.Semantic proximity Read ↗

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.Semantic proximity Read ↗

Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.Semantic proximity Read ↗

A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk.Semantic proximity Read ↗

Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5‐fluorouracil–based chemotherapySemantic proximity Read ↗

Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

A Practical Non-Extraction Direct Liquid Chromatography Method for Determination of Thiopurine S-Methyltransferase Activity in Inflammatory Bowel Disease.Semantic proximity Read ↗

Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.Semantic proximity Read ↗

Purification and characterization of dihydropyrimidine dehydrogenase from human liver.Semantic proximity Read ↗

Evaluation of an oral uracil loading test to identify DPD‐deficient patients using a limited sampling strategySemantic proximity Read ↗

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.